Curcumin and Its Potential to Target the Glycolytic Behavior of Lactate-Acclimated Prostate Carcinoma Cells with Docetaxel
2024

Curcumin's Role in Targeting Glycolysis in Prostate Cancer Cells

publication 10 minutes Evidence: moderate

Author Information

Author(s): Dongsic Choi, Jun Gi Lee, Su-Hak Heo, Moon-Kyen Cho, Hae-Seon Nam, Sang-Han Lee, Yoon-Jin Lee

Primary Institution: Soonchunhyang University

Hypothesis

Can curcumin effectively target the glycolytic behavior of lactate-acclimated prostate carcinoma cells to improve sensitivity to docetaxel?

Conclusion

Curcumin may enhance treatment outcomes in prostate cancer by targeting glycolysis and overcoming docetaxel resistance.

Supporting Evidence

  • Curcumin combined with docetaxel reduced tumor size and weight in a xenograft model.
  • Lactate-acclimated prostate cancer cells showed increased growth and reduced sensitivity to docetaxel.
  • HK2 knockdown led to decreased cell growth and increased apoptosis in prostate cancer cells.
  • Curcumin's anti-glycolytic effects were consistent across 2D and 3D culture models.

Takeaway

Curcumin helps fight prostate cancer by making cancer cells less resistant to a common drug called docetaxel, which usually doesn't work well on these cells.

Methodology

The study involved cell culture experiments, Western blotting, and xenograft models to assess the effects of curcumin on prostate cancer cells.

Potential Biases

Potential bias due to the use of specific cell lines and the controlled laboratory environment.

Limitations

The study primarily focused on specific prostate cancer cell lines and may not fully represent all prostate cancer types.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3390/nu16244338

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication